- Immix Biopharma (IMMX, Financial) to host a virtual KOL event on June 3, 2025, to discuss NEXICART-2 Phase 1/2 trial data.
- Interim clinical data from cell therapy NXC-201 in relapsed/refractory AL Amyloidosis will be the focus.
- Experts from Memorial Sloan-Kettering, Cleveland Clinic, and Karmanos Cancer Institute to present at the event.
Immix Biopharma, Inc. (IMMX), a clinical-stage biopharmaceutical company, is set to host a virtual Key Opinion Leader (KOL) event on June 3, 2025, at 3:00pm ET. The event will provide insights into the interim clinical data from the NEXICART-2 Phase 1/2 clinical trial, featuring their cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis. This follows its presentation at the 2025 American Society of Clinical Oncology (ASCO) conference.
The virtual session will include presentations by esteemed medical experts, such as Dr. Heather Landau from Memorial Sloan-Kettering Cancer Center, Dr. Shahzad Raza from the Cleveland Clinic, and Dr. Jeffrey Zonder from Karmanos Cancer Institute. These specialists will share valuable clinical experiences with NXC-201 and discuss advancements in AL Amyloidosis treatment.
A live Q&A session will be held after the presentations, offering investors and interested parties an opportunity to engage directly with the experts. The event can be accessed via a webcast through the provided link or on the Immix website under Presentations & Events.
The NEXICART-2 trial, a single-arm multi-site U.S. Phase 1/2 study, evaluates the safety and efficacy of the BCMA-targeted CAR-T cell therapy, NXC-201. The trial aims to enroll 40 patients, focusing on those with preserved heart function who have not undergone prior BCMA-targeted therapy. Initial data from the study has indicated promising complete response rates with no neurotoxicity observed, highlighting its potential for expanding treatment avenues in AL Amyloidosis and other serious conditions.
